Rituximab possible treatment option for patients with primary biliary cirrhosis Eureka! Science News An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol. |
